Please login to the form below

Not currently logged in
Email:
Password:

inflammatory conditions

This page shows the latest inflammatory conditions news and features for those working in and with pharma, biotech and healthcare.

Gilead and Galapagos JAK contender scores in RA trial

Gilead and Galapagos JAK contender scores in RA trial

The results are further good news for the partners and their inflammatory conditions contender, which is also being studied in ulcerative colitis, Crohn’s disease and ankylosing spondylitis.

Latest news

  • Sanofi and Ablynx sign €2.4bn nanobody deal Sanofi and Ablynx sign €2.4bn nanobody deal

    Sanofi and Ablynx sign 2.4bn nanobody deal. The duo will develop immune-mediated inflammatory disease candidates. ... Through external partnerships like these, combined with our internal R&D expertise, we aim to transform the treatment landscape for

  • FDA verdict on Amgen's Humira biosimilar due in September FDA verdict on Amgen's Humira biosimilar due in September

    FDA verdict on Amgen's Humira biosimilar due in September. Begins review the version of AbbVie's big-selling anti-inflammatory drug. ... The US FDA has started its review of Amgen's biosimilar version of big-selling anti-inflammatory drug Humira, with an

  • Roche drops superbug partnership with Polyphor Roche drops superbug partnership with Polyphor

    Anti-Inflammatory deal. After jettisoning the Polyphor project, Roche added another research deal in the form of a licensing agreement for a novel, oral small molecule inhibitor of Vascular Adhesion Protein ... patients with various inflammatory

  • Novartis' Cosentyx cleared for wider use in Europe Novartis' Cosentyx cleared for wider use in Europe

    Cosentyx "has the potential to become a new standard of care for these common but under-treated inflammatory conditions," he added.

  • Lilly’s baricitinib beats Humira in trial for RA Lilly’s baricitinib beats Humira in trial for RA

    Baricitinib is a once-daily, oral, selective JAK1 and JAK2 inhibitor. JAK-dependant cytokines have been implicated in the pathogenesis of a number of inflammatory and autoimmune diseases, suggesting that they ... may be useful for the treatment of a

More from news
Approximately 1 fully matching, plus 24 partially matching documents found.

Latest Intelligence

  • Medius Deal Watch table for April 2015 Medius Deal Watch table for April 2015

    49. Mesoblast / Celgene. Minority investment and option to license. stem-cell product candidates for conditions including inflammatory bowel disease and certain oncological indications.

  • Pharma deals in April 2015 Pharma deals in April 2015

    Celgene, will gain six months right of first refusal on Mesoblast's stem-cell product candidates for conditions including inflammatory bowel disease and certain oncological indications, for global rights (excluding Japan),

  • Deal Watch table for April 2014 Deal Watch table for April 2014

    7, 100. Questcor/ Mallinckrodt. Acquisition. Acthar Gel (repository corticotropin) for “ difficult-to-treat” autoimmune/ inflammatory conditions.

  • Pharma deals during April 2014 Pharma deals during April 2014

    This gives Mallinckrodt, Acthar Gel (repository corticotropin), which is FDA approved for 19 “ difficult-to-treat” autoimmune and inflammatory associated conditions and currently primarily used to treat multiple sclerosis relapses, proteinuria

  • Biosimilars: friend or foe for healthcare systems? Biosimilars: friend or foe for healthcare systems?

    Here we consider how the European landscape for biosimilars is ripe for transformation as more mAbs or anti-TNFs (Tumour Necrosis Factors) for inflammatory conditions such as rheumatoid arthritis enter the

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hayward Medical Communications

Hayward Medical Communications has been supporting partners in every sector of the healthcare industry to deliver evidence-based, clinically relevant and...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...

Infographics